Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK plus NSCLC: Final Report of the ASCEND-8 Trial

被引：1

作者：

Cho, B. C. ^{[1
]}

Kim, D. ^{[2
]}

Laurie, S. ^{[3
]}

Mckeage, M. ^{[4
]}

Borra, G. ^{[5
]}

Park, K. ^{[6
]}

Kim, S. ^{[7
]}

Ghosn, M. ^{[8
]}

Ardizzoni, A. ^{[9
]}

Greystoke, A. ^{[10
]}

Izquierdo, M. ^{[11
]}

Wang, Y. ^{[11
]}

Wang, L. ^{[11
]}

Wrona, A. ^{[12
]}

机构：

[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Ottawa Hosp Canc Ctr, Ottawa, AB, Canada

[4] Univ Auckland, Auckland, New Zealand

[5] Az Osped Univ Maggiore Carita, Novara, Italy

[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[7] Univ Uslan, Coll Med, Asan Med Ctr, Seoul, South Korea

[8] St Joseph Univ, Beirut, Lebanon

[9] S Orsola Malpighi Univ Hosp, Bologna, Italy

[10] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England

[11] Novartis Pharmaceut, E Hanover, NJ USA

[12] Med Univ Gdansk, Gdansk, Poland

来源：

关键词：

ALK plus NSCLC; ALK inhibitors; ceritinib;

D O I：

10.1016/j.jtho.2021.01.1204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P84.05

引用

页码：S657 / S658

页数：2